BioSpace News Archive

Vedanta Biosciences today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.

Kura Oncology, Inc. today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit at 2:00 p.m. ET / 11:00 a.m. PT on Tuesday, December 5, 2023.

Onconova Therapeutics, Inc. today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be offered in GE HealthCare’s new MyBreastAI Suite* offering.

Sagimet Biosciences Inc. will present preclinical data at the 7th Obesity and NASH Drug Development Summit on November 28, 2023, in Boston.

DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI® Injection 0.3mg and SYMJEPI® Injection 0.15mg products from USWM, LLC.

NANO-X IMAGING LTD today announced results for the third quarter ended September 30, 2023 and provided a business update.

Banjo Health, a leader in generative AI-powered prior authorization software, and Opala, an interoperability platform for seamless real-time data integration in healthcare, are excited to announce their strategic partnership.

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.

AIM ImmunoTech Inc. announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023.